Tuberculosis: Current Treatments and Investigational Therapies
3HP for Latent TB Infection Treatment | CDC
Adherence to nine-month isoniazid for latent tuberculosis infection in healthcare workers: a prospective study in a tertiary hospital | Scientific Reports
Rifapentine Dosing for Children With Latent Tuberculosis Infection in... | Download Table
12-dose Isoniazid/Rifapentine Regimen for Latent TB Infection Treatment | National Prevention Information Network | Connecting public health professionals with trusted information and each other
What You Need to Know About Your Medicine for Latent Tuberculosis (TB) Infection – Isoniazid and Rifapentine | National Prevention Information Network | Connecting public health professionals with trusted information and each other
3HP for Latent TB Infection Treatment | CDC
Benefit of treatment of latent tuberculosis infection in individual patients | European Respiratory Society
Treatment for Latent TB Infection in Adults | Download Table
Latent Tuberculosis Infection (LTBI) Treatments
Management of latent Mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries | European Respiratory Society
Cureus | Use of Isoniazid Monotherapy in Comparison to Rifamycin-Based Regimen for the Treatment of Patients With Latent Tuberculosis: A Systematic Review | Article
Guidelines for the treatment of latent tuberculosis infection: Recommendations from the National Tuberculosis Controllers Association and CDC, 2020 - Sterling - 2020 - American Journal of Transplantation - Wiley Online Library
4 months of rifampin for latent TB shows promise
Treatment options for latent tuberculosis infection - Latent tuberculosis infection: updated and consolidated guidelines for programmatic management - NCBI Bookshelf
Latent TB Treatment: Shorter is Better | McGill University Health Centre
CDC Recommends New Treatment Regimen for Latent Mycobacterium Tuberculosis Infection | AAFP